Daniel P. O’Day

Daniel P. O’Day is a seasoned executive with an extensive background in the pharmaceutical industry. Raised with a strong academic foundation, he built his early career on the principles of science and business management, having earned his degrees in biology and business administration from prestigious institutions. " " " "

Before joining GILD, he amassed over three decades of experience at Roche Pharmaceuticals, where he held various executive roles and was instrumental in steering the company's pharmaceutical and diagnostics divisions across North America, Europe, and Asia. " " His leadership journey at Roche also included pivotal board roles with companies such as Genentech and Flatiron Health.

Upon joining GILD in March 2019 as both Chairman and Chief Executive Officer, he brought his deep industry insights and commitment to innovation, driving the company’s strategy to address unmet medical needs and navigate evolving global healthcare challenges. " " His role has been central to enhancing the company’s pipeline and maintaining its leadership in the pharmaceutical market.

In addition to his executive duties at GILD, he serves as the Board Chair for the Pharmaceutical Research and Manufacturers of America (PhRMA), underscoring his influential presence in shaping industry standards and advancing healthcare initiatives. " "

Performance Shares

Corporate Bonus (Non-Equity Incentive Plan)